| Cat.No. | Name | Information |
|---|---|---|
| M2167 | (+)-JQ1 | (+)-JQ1 is a BET bromodomain inhibitor that acts on BRD4(2) with an IC50 of 33 nM and binds to all bromodomain domains in the BET family, but not to bromodomain domains outside the BET family. JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway, and JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway. |
| M6118 | 666-15 | 666-15 is a potent and selective CREB inhibitor with an IC50 of 81 nM. |
| M2096 | I-BET151 | I-BET151 (GSK1210151A) is an inhibitor of the BET family with IC50 of 0.5 μM, 0.25 μM and 0.79 μM for BRD2, BRD3 and BRD4, respectively. |
| M2903 | OTX015 (Birabresib) | OTX015 is a potent BET bromodomain inhibitor with EC50 ranging from 10 to 19 nM for BRD2, BRD3, and BRD4. |
| M2190 | I-BET-762 | I-BET-762 (GSK525762) is a selective small molecule BET inhibitor. |
| M7126 | PF CBP1 | PF CBP1 is a selective CBP/p300 bromodomain inhibitor. |
| M9218 | ABBV-744 | ABBV-744 is a first-in-class, orally active and selective inhibitor of the BDII domain of the BET family of proteins with IC50 values of 4-18 nM for BRD2, BRD3, BRD4, and BRDT for AML and metastatic desmoplasia-resistant prostate cancer. |
| M50205 | OPN-2853 | OPN-2853 is a bromodomain protein-4 (BRD4) inhibitor that can be used in studies related to hematologic and lymphatic disorders. |
| M49506 | HDAC/JAK/BRD4-IN-1 | HDAC/JAK/BRD4-IN-1 is a potent HDAC/JAK/BRD4 triple inhibitor. |
| M49352 | VYN-201 | VYN-201 is a novel pan-BET inhibitor for studies related to idiopathic pulmonary fibrosis. |
| M45248 | NEO1132 | NEO1132 is a novel, orally active dual inhibitor of BET and CBP/EP300 with antitumor activity. |
| M45246 | Y08197 | Y08197 is a novel selective CBP/EP300 bromodomain inhibitor for prostate cancer-related studies. |
| M45239 | FT-6876 | FT-6876 is a selective inhibitor of the CBP/p300 bromodomain for studies related to solid tumors. |
| M45236 | DS17701585 | DS17701585 is a selective, orally active inhibitor of EP300 and CBP with IC50 values of 0.040, 0.15, 0.45, and 0.70 µM for CBP, EP300, H3K27, and SOX2, respectively.CAS 번호128-52-56-5 |
| M45235 | FT-7051 | FT-7051 is a p300-CBP transcription factor inhibitor that can be used in studies related to prostate cancer. |
| M43412 | Tz-Thalidomide | Tz-Thalidomide is a tetrazine tagged Thalidomide. |
| M43411 | PROTAC BRD9 Degrader-6 | PROTAC BRD9 Degrader-6 is a potent degrader of BRD9 (IC50=0.13 nM), can be used for research of BAF complex-related disorders. |
| M41670 | DBr-1 | DBr-1 is a potent BRD9 degrader. |
| M41669 | RX-37 | RX-37 is a selective BET inhibitor. |
| M41668 | BET-IN-16 | BET-IN-16 is a BET inhibitor. |
| M41667 | BRD4-IN-4 | BRD4-IN-4 is a BRD4 inhibitor (IC50=6.83 μM). |
| M41666 | WWL0245 | WWL0245 is a potent and seletive BRD4 PROTAC. |
| M41665 | TMX1 | TMX1 is a BRD4 covalent molecular glue degrader. |
| M41664 | SJ1461 | SJ1461 is a potent and orally active BET inhibitor. |
| M41663 | BRD4 Inhibitor-28 | BRD4 Inhibitor-28 is an orally active BRD4 Inhibitor. |
| M41662 | IV-275 | IV-275 is an inhibitor of both BRG1 and BRM bromodomains. |
| M41661 | BET bromodomain inhibitor 3 | BET bromodomain inhibitor 3 is BET bromodomain inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
